Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Diamicron, Gliclada, Glynase, Minodiab
Gliclazide is an oral anti-diabetic medication of the sulfonylurea class, second generation, used to treat type 2 diabetes mellitus. It works primarily by stimulating insulin release from the beta cells in the pancreas. Gliclazide also improves peripheral insulin sensitivity and reduces hepatic glucose production. It is generally well-tolerated and less prone to causing hypoglycemia than some other sulfonylureas.
For the treatment of type 2 diabetes mellitus when diet and exercise alone are not sufficient.
Outcome:
Increased risk of hypoglycemia or hyperglycemia
Mechanism:
Alcohol can interfere with the metabolism of gliclazide.
Outcome:
Masking of hypoglycemic symptoms
Mechanism:
Beta-blockers can mask the adrenergic symptoms of hypoglycemia.
Outcome:
Slight increase in hypoglycemic effect
Mechanism:
NSAIDs may displace gliclazide from protein binding sites.
Most likely new formulation: sustained-release combination with metformin (Year 2025, 75% confidence)
Based on current usage trends and clinical trial data, there is a 90% likelihood that gliclazide will maintain its approved status for the treatment of type 2 diabetes.
Antidiabetic Agent, Sulfonylurea (Second Generation)
Sulfonylurea